Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 10, 2024

SELL
$392.81 - $485.53 $9,034 - $11,167
-23 Reduced 4.09%
540 $253,000
Q1 2024

Apr 25, 2024

BUY
$407.69 - $446.08 $229,529 - $251,143
563 New
563 $235,000
Q3 2022

Nov 03, 2022

BUY
$273.83 - $305.53 $190,859 - $212,954
697 New
697 $202,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Life Pro Asset Management Portfolio

Follow Life Pro Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Life Pro Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Life Pro Asset Management with notifications on news.